Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is an ongoing Phase 3 trial with no results reported; the registry record describes only planned enrollment, design, and primary outcome measures.
Phase 2b dose-range finding trial with completed recruitment but no results posted; registry record only describes planned methods and endpoints, not outcomes.